{"id":22725,"date":"2020-09-16T10:33:19","date_gmt":"2020-09-16T08:33:19","guid":{"rendered":"https:\/\/kymos.com\/news\/socis-globals-biofarmaceutics\/"},"modified":"2020-09-16T10:33:19","modified_gmt":"2020-09-16T08:33:19","slug":"socis-globals-biofarmaceutics","status":"publish","type":"post","link":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/","title":{"rendered":"Socis globals biofarmac\u00e8utics"},"content":{"rendered":"

Coneix Pablo Cobo: el principal l\u00edder d’opini\u00f3 de KYMOS en el desenvolupament de f\u00e0rmacs biol\u00f2gics<\/strong><\/span><\/h3>\n
\n
\n
\n
\n

El nostre cap de proves biofarmac\u00e8utiques, Pablo Cobo, graduat en qu\u00edmica i pioner en productes biol\u00f2gics, recorda els seus primers dies a Ipsen, quan el desenvolupament de productes pept\u00eddics era for\u00e7a diferent:<\/span><\/p>\n

\u00abL’any 1994, les empreses biofarmac\u00e8utiques feien la major part del seu treball de desenvolupament internament, per\u00f2 a causa dels elevats costos del personal i la instrumentaci\u00f3 especialitzats van comen\u00e7ar a externalitzar les activitats de prova a organitzacions de recerca externes\u00bb, afirma el Sr. Cobo. \u00abAvui dia, les empreses que no tenen la infraestructura necess\u00e0ria poden desenvolupar biol\u00f2gics i biosimilars espec\u00edfics de manera rendible gr\u00e0cies a CRO i CDMO especialitzades.\u00bb <\/em><\/span><\/p>\n

Reptes actuals en les proves de biof\u00e0rmacs <\/strong><\/span><\/p>\n

El departament biofarmac\u00e8utic de KYMOS se centra en el control de qualitat de productes biol\u00f2gics innovadors i biosimilars, els dos principals segments biofarmac\u00e8utics, per\u00f2 la demanda d’estudis de comparabilitat de biosimilars ha augmentat significativament en els darrers anys. Pablo Cobo t\u00e9 una idea de per qu\u00e8 podria ser: <\/span><\/p>\n

\u201cDe la mateixa manera que va passar amb els gen\u00e8rics als anys 80, moltes biofarmac\u00e8utiques de gran \u00e8xit veuen com les seves patents caduquen i ara tenen una gran demanda com a biosimilars. Actualment treballem amb desenes de biosimilars i transferim m\u00e8todes de clients d’arreu del m\u00f3n: anticossos monoclonals (mAbs) d’\u00c0sia; hormones recombinants d’Am\u00e8rica Llatina; factors de creixement d’Europa… Treballar amb biosimilars i els seus biol\u00f2gics de refer\u00e8ncia \u00e9s un repte perqu\u00e8 s\u00f3n tan diversos com molecularment complexos i estar equipats per realitzar tots els diferents assaigs necessaris per a la seva caracteritzaci\u00f3 no sempre \u00e9s l’opci\u00f3 m\u00e9s eficient. Com a resultat, les empreses interessades a entrar al mercat dels biosimilars tendeixen a externalitzar els serveis de proves m\u00e9s sovint que les empreses de gen\u00e8rics abans.\u201d <\/em><\/span><\/p>\n

Aquesta tend\u00e8ncia positiva \u00e9s tan forta que, malgrat el brot de coronavirus, l’equip de Pablo ha experimentat un augment de 2,5 vegades en la demanda de serveis i un augment del 44% en el valor mitj\u00e0 dels pressupostos aprovats en comparaci\u00f3 amb el mateix per\u00edode del 2019.<\/span>
\n\u00abPreveiem que a mitj\u00e0 termini els biosimilars representaran el percentatge m\u00e9s gran de l’activitat del nostre departament\u00bb,<\/em> conclou el Sr. Cobo.<\/span><\/p>\n

Qu\u00e8 pot oferir l’equip de proves biofarmac\u00e8utiques de KYMOS que altres CRO?<\/strong><\/span><\/p>\n

Pablo Cobo est\u00e0 orgull\u00f3s del seu equip d’experts formats internament i de les seves instal\u00b7lacions ben equipades, per\u00f2 hi ha una altra ra\u00f3 important per la qual els nostres clients trien KYMOS com a laboratori de refer\u00e8ncia:<\/span><\/p>\n

\u00abMolts dels nostres clients provenen de pa\u00efsos com la Xina, Corea del Sud, Singapur, el L\u00edban, l’\u00cdndia o l’Argentina, on es poden trobar altres alternatives a la CRO i regulacions favorables a les empreses\u00bb,<\/em> comen\u00e7a el Sr. Cobo. \u00abNo obstant aix\u00f2, tots els medicaments fabricats fora de la UE\/EEE, inclosos els biof\u00e0rmacs, han de ser analitzats per un laboratori certificat de la UE abans de la seva comercialitzaci\u00f3. El fet que tamb\u00e9 siguem importadors i fabricants certificats, capa\u00e7os de proporcionar serveis d’importaci\u00f3, proves de lots i alliberament de lots QP, fa que sigui m\u00e9s convenient per a aquestes empreses transferir els seus m\u00e8todes de fabricaci\u00f3 a KYMOS: podem ajudar-les durant tot el proc\u00e9s\u00bb.<\/em> <\/span><\/p>\n

Un d’aquests clients globals \u00e9s CELLTRION, una empresa sud-coreana l\u00edder especialitzada en anticorps monoclonals biosimilars i productes biol\u00f2gics innovadors. Yong Suk Yang, gerent de l’equip d’operacions de control de qualitat global de CELLTRION, comparteix la seva experi\u00e8ncia treballant amb KYMOS: <\/span><\/p>\n

“Actualment estem desenvolupant diversos projectes biosimilars nous m\u00e9s enll\u00e0 del nostre producte estrella Remsima (un biosimilar d’infliximab venut com a Inflectra als EUA) i considerem KYMOS una de les millors CRO d’Europa per al llan\u00e7ament i les proves de f\u00e0rmacs.” <\/em><\/span><\/p>\n

Pablo Cobo afegeix a les paraules del Sr. Yang la seva opini\u00f3 personal sobre projectes anteriors:<\/span><\/p>\n

\u00abCELLTRION \u00e9s una empresa amb m\u00e8todes anal\u00edtics robustos i un coneixement profund de la seva cartera. Treballar per a ells ha estat un veritable privilegi, ja que ens ha donat l’oportunitat d’implementar t\u00e8cniques de caracteritzaci\u00f3 d’antic\u00f2s monoclonals d’alt rendiment com ara l’electroforesi capil\u00b7lar o l’enfocament isoel\u00e8ctric per imatge de Protein Simple (iCE3)\u00bb.<\/em> El Sr. Cobo continua: \u00abConsidero els projectes dels nostres clients com una col\u00b7laboraci\u00f3 que funciona en ambd\u00f3s sentits: els assistim en totes les seves necessitats de control de qualitat i adquirim valuosos coneixements en el proc\u00e9s. Despr\u00e9s de molts anys provant biol\u00f2gics i biosimilars innovadors, la nostra experi\u00e8ncia parla per si sola\u00bb.<\/em><\/span><\/p>\n

Expectatives de futur<\/strong><\/span>
\nEl 2012, el departament d’assajos biofarmac\u00e8utics de KYMOS estava format per nom\u00e9s dos membres. Avui, despr\u00e9s d’una reubicaci\u00f3 i dues ampliacions de laboratori, l’equip de Pablo ha crescut gaireb\u00e9 deu vegades i gaudeix d’una previsi\u00f3 de creixement optimista impulsada per les tend\u00e8ncies actuals d’externalitzaci\u00f3. El seu treball constant i fiable ha rebut comentaris positius de clients a tot el m\u00f3n i ha situat KYMOS com un dels 10 millors prove\u00efdors de serveis biosimilars a nivell mundial<\/a><\/strong> . Aix\u00ed doncs, amb una posici\u00f3 tan envejable, qu\u00e8 m\u00e9s podria demanar Pablo Cobo? La seva resposta \u00e9s immediata: <\/span><\/p>\n

\u00abUn laboratori nou! Acabem d’ampliar les nostres instal\u00b7lacions l’any passat, per\u00f2 ja ens quedem sense espai!\u00bb<\/em><\/span><\/p>\n

 <\/p>\n

Aqu\u00ed podeu veure m\u00e9s informaci\u00f3 sobre les proves de biosimilars<\/strong><\/a> de<\/a> KYMOS ; la caracteritzaci\u00f3 de biol\u00f2gics i biosimilars<\/a><\/strong> i la bioan\u00e0lisi de biol\u00f2gics i biosimilars<\/strong><\/a> o contactar amb nosaltres a commercial@kymos.com<\/a> .<\/span><\/p>\n

CELLTRION \u00e9s una for\u00e7a l\u00edder en la ind\u00fastria farmac\u00e8utica coreana. Van llan\u00e7ar el primer “biosimilar d’anticossos” del m\u00f3n des d’un pa\u00eds amb un sector farmac\u00e8utic relativament poc desenvolupat i planegen cr\u00e9ixer com a empresa biofarmac\u00e8utica global amb enfocaments \u00fanics per a productes farmac\u00e8utics de mol\u00e8cules petites i nous negocis com el negoci de la plataforma Ubiquitous-healthcare. Per a m\u00e9s informaci\u00f3 sobre CELLTRION, poseu-vos en contacte amb ells a contact@celltrion.com<\/a> . <\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Coneix Pablo Cobo: el principal l\u00edder d’opini\u00f3 de KYMOS en […]<\/p>\n","protected":false},"author":6,"featured_media":14964,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[107],"tags":[],"class_list":["post-22725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-kymos-group-ca"],"acf":[],"yoast_head":"\nSocis globals biofarmac\u00e8utics | Kymos<\/title>\n<meta name=\"description\" content=\"Pablo Cobo, cap de proves biofarmac\u00e8utiques de CELLTRION, comparteix la seva experi\u00e8ncia al mercat biofarmac\u00e8utic\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Socis globals biofarmac\u00e8utics | Kymos\" \/>\n<meta property=\"og:description\" content=\"Pablo Cobo, cap de proves biofarmac\u00e8utiques de CELLTRION, comparteix la seva experi\u00e8ncia al mercat biofarmac\u00e8utic\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-16T08:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"437\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"Socis globals biofarmac\u00e8utics\",\"datePublished\":\"2020-09-16T08:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/\"},\"wordCount\":1065,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"articleSection\":[\"Kymos Group\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/\",\"name\":\"Socis globals biofarmac\u00e8utics | Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"datePublished\":\"2020-09-16T08:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Pablo Cobo, cap de proves biofarmac\u00e8utiques de CELLTRION, comparteix la seva experi\u00e8ncia al mercat biofarmac\u00e8utic\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"width\":800,\"height\":437},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/socis-globals-biofarmaceutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/ca\\\/inici\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Socis globals biofarmac\u00e8utics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Socis globals biofarmac\u00e8utics | Kymos","description":"Pablo Cobo, cap de proves biofarmac\u00e8utiques de CELLTRION, comparteix la seva experi\u00e8ncia al mercat biofarmac\u00e8utic","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/","og_locale":"ca_ES","og_type":"article","og_title":"Socis globals biofarmac\u00e8utics | Kymos","og_description":"Pablo Cobo, cap de proves biofarmac\u00e8utiques de CELLTRION, comparteix la seva experi\u00e8ncia al mercat biofarmac\u00e8utic","og_url":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/","og_site_name":"Kymos","article_published_time":"2020-09-16T08:33:19+00:00","og_image":[{"width":800,"height":437,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"Escrit per":"Joan Puig de Dou","Temps estimat de lectura":"5 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"Socis globals biofarmac\u00e8utics","datePublished":"2020-09-16T08:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/"},"wordCount":1065,"image":{"@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","articleSection":["Kymos Group"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/","url":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/","name":"Socis globals biofarmac\u00e8utics | Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","datePublished":"2020-09-16T08:33:19+00:00","author":{"@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Pablo Cobo, cap de proves biofarmac\u00e8utiques de CELLTRION, comparteix la seva experi\u00e8ncia al mercat biofarmac\u00e8utic","breadcrumb":{"@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","width":800,"height":437},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/ca\/news\/socis-globals-biofarmaceutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/ca\/inici\/"},{"@type":"ListItem","position":2,"name":"Socis globals biofarmac\u00e8utics"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/ca\/#website","url":"https:\/\/kymos.com\/ca\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/ca\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/comments?post=22725"}],"version-history":[{"count":0,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22725\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media\/14964"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media?parent=22725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/categories?post=22725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/tags?post=22725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}